• Consensus Rating: Buy
  • Consensus Price Target: $11.67
  • Forecasted Upside: 941.67%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.12
▼ -0.02 (-1.75%)

This chart shows the closing price for FEMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Femasys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FEMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FEMY

Analyst Price Target is $11.67
▲ +941.67% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Femasys in the last 3 months. The average price target is $11.67, with a high forecast of $13.00 and a low forecast of $10.00. The average price target represents a 941.67% upside from the last price of $1.12.

This chart shows the closing price for FEMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Femasys. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00Low
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00Low
4/1/2024Chardan CapitalReiterated RatingBuy ➝ Buy$12.00Low
4/1/2024HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $12.00Low
3/21/2024Chardan CapitalReiterated RatingBuy ➝ Buy$12.00Low
3/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
3/20/2024JonestradingBoost TargetBuy ➝ Buy$7.00 ➝ $10.00Low
11/14/2023HC WainwrightLower TargetBuy ➝ Buy$13.00 ➝ $10.00Low
9/29/2023HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $13.00Low
9/26/2023JonestradingBoost TargetBuy ➝ Buy$5.00 ➝ $7.00Low
8/11/2023Chardan CapitalReiterated RatingBuy ➝ Buy$10.00Low
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00Low
3/30/2023Chardan CapitalLower TargetBuy$12.00 ➝ $10.00Low
11/11/2022Chardan CapitalLower TargetBuy$15.00 ➝ $12.00Low
10/20/2022HC WainwrightLower TargetBuy$8.00 ➝ $5.00Low
6/17/2022Maxim GroupInitiated CoverageBuy$5.00Medium
3/25/2022Chardan CapitalLower TargetBuy$25.00 ➝ $18.00Medium
3/24/2022HC WainwrightInitiated CoverageBuy$8.00High
7/13/2021JonestradingInitiated CoverageBuy$8.45High
7/13/2021Chardan CapitalInitiated CoverageBuy$25.00High
(Data available from 7/16/2019 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/18/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/17/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/17/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/16/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/16/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

Femasys logo
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Read More

Today's Range

Now: $1.12
Low: $1.10
High: $1.15

50 Day Range

MA: $1.16
Low: $0.96
High: $1.42

52 Week Range

Now: $1.12
Low: $0.25
High: $4.75

Volume

95,054 shs

Average Volume

444,334 shs

Market Capitalization

$24.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Femasys?

The following sell-side analysts have issued stock ratings on Femasys in the last twelve months: Chardan Capital, HC Wainwright, and Jonestrading.
View the latest analyst ratings for FEMY.

What is the current price target for Femasys?

3 Wall Street analysts have set twelve-month price targets for Femasys in the last year. Their average twelve-month price target is $11.67, suggesting a possible upside of 941.7%. HC Wainwright has the highest price target set, predicting FEMY will reach $13.00 in the next twelve months. Jonestrading has the lowest price target set, forecasting a price of $10.00 for Femasys in the next year.
View the latest price targets for FEMY.

What is the current consensus analyst rating for Femasys?

Femasys currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FEMY will outperform the market and that investors should add to their positions of Femasys.
View the latest ratings for FEMY.

What other companies compete with Femasys?

How do I contact Femasys' investor relations team?

The company's listed phone number is 770-500-3910 and its investor relations email address is [email protected]. The official website for Femasys is www.femasys.com. Learn More about contacing Femasys investor relations.